HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during Adefovir dipivoxil therapy

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 813-818

  Tseng, Kuo Chih ^a,b   Cheng, Pin Nan ^c   Wu, I Chin ^c   Chang, Chin Kuo ^d   Chou, An Liang ^a   Liu, Wen Chun ^e   Chang, Ting Tsung ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF ULSTER   (United Kingdom)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Adefovir; Chronic hepatitis B; Genotype; HBeAg seroconversion; HBV DNA

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; PLACEBO; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 67651237073     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Shikata T, Karasawa T, Abe K, et al: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136:571-576. (Pubitemid 8211390)
2. Milich D, Liang TJ: Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38:1075-1086. (Pubitemid 37314815)
3. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744-748. (Pubitemid 11123366)
4. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216-219. (Pubitemid 13224257)
5. Niederau C, Heintges T, Lange S, et al: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Eng J Med 1996; 334:1422-1427. (Pubitemid 26157437)
6. Hsu YS, Chien RN, Yeh CT, et al: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527. (Pubitemid 34966908)
7. Hoofnagle JH, Peters M, Mullen KD, et al: Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325. (Pubitemid 18256902)
8. Lok AS, Ghany MG, Watson G, Ayola B: Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998; 5:171-178. (Pubitemid 28374726)
9. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10:761-763. (Pubitemid 19270158)
10. Perrillo RP, Schiff ER, Davis GL, et al: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Eng J Med 1990; 323:295-301. (Pubitemid 20237094)
11. Di Bisceglie AM, Fong TL, Fried MW, et al: A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88:1887-1892. (Pubitemid 23324405)
12. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Eng J Med 1997; 336:347-356.
13. Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30:770-774. (Pubitemid 29409422)
14. Perrillo RP, Lai CL, Liaw YF, et al: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186-194. (Pubitemid 34700777)
15. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL: Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46:1695-1703.
16. Kramata P, Votruba I, Otova B, Holy A: Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 49:1005-1011. (Pubitemid 26182989)
17. Cundy KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36:127-143. (Pubitemid 29121686)
18. Marcellin P, Chang TT, Lim SG, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Eng J Med 2003; 348:808-816. (Pubitemid 36245757)
19. Knodell RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435. (Pubitemid 12218164)
20. Lindh M, Gonzalez JE, Norkrans G, Horal P: Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Methods 1998; 72:163-174. (Pubitemid 28306959)
21. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H: A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
22. Yamaura T, Tanaka E, Matsumoto A, et al: A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutants in the precore region and core promoter. J Med Virol 2003; 70:545-552. (Pubitemid 36734718)
23. Jung MC, Pape GR: Immunology of hepatitis B infection. Lancet Infect Dis 2002; 2:43-50.
24. Chang TT, Gish RG, de Man R, et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Eng J Med 2006; 354:1001-1010. (Pubitemid 43357804)
25. Lau GK, Piratvisuth T, Luo KX, et al: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Eng J Med 2005; 352:2682-2695. (Pubitemid 41007823)
26. Lai CL, Gane E, Liaw YF, et al: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
27. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007; 45:507-539.